SavedAdd your journal

Journals / Ankara Üniversitesi Eczacılık Fakültesi Dergisi / 2026 / Cilt: 50 Sayı: 3

ACNE VULGARIS TREATMENT AND RETINOIC ACID DERIVATIVES

AKNE VULGARİS TEDAVİSİ VE RETİNOİK ASİT TÜREVLERİ

Özden Tarı(CUKUROVA UNIVERSITY, FACULTY OF PHARMACY)0000-0001-9280-6594
Gözde Tari(CUKUROVA UNIVERSITY, FACULTY OF PHARMACY)0009-0007-2880-6195
Pages
860–878
Publication Date
2026-09-19
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, optimising formulations that will minimise these side effects will increase the success of acne treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Acne vulgaris is a common chronic inflammatory disease all over the world and affects people both physically and psychologically.
📊
Key Findings & Data:Various antibiotics and retinoic acid derivatives are used in its treatment.
💡
Conclusion & Impact:Therefore, optimising formulations that will minimise these side effects will increase the success of acne treatment.
🔬Design:Derleme
📍Scope:Comprehensive Sample
⚙️Variables:Akne vulgaris · izotretinoin · retinoik asit

Abstract

Objective: Acne vulgaris is a common chronic inflammatory disease all over the world and affects people both physically and psychologically. Various antibiotics and retinoic acid derivatives are used in its treatment. The aim of the study is to examine retinoic acid derivatives, which are the basic building blocks of the treatment of this disease, and current studies aimed at reducing the side effects of these derivatives. Result and Discussion: Retinoids and antibiotics are used as complementary agents in the treatment of acne vulgaris. While retinoids provide a long-term solution, antibiotics are used for short periods of time due to the development of resistance. Isotretinoin, the only systemically used retinoic acid derivative, is the only derivative that permanently affects the course of the disease in severe and resistant acne. Although the modifications made to improve these derivatives change the activity and selectivity, some side effects appear to persist. Therefore, optimising formulations that will minimise these side effects will increase the success of acne treatment.

Özet

Amaç: Akne vulgaris tüm dünyada sık karşılaşılan bir kronik enflamatuar hastalık olup insanları hem fiziksel hem de psikolojik açıdan etkilemektedir. Tedavisinde çeşitli antibiyotikler ve retinoik asit türevleri kullanılmaktadır. Çalışmadaki amaç bu hastalığın tedavisinin temel yapı taşı olan retinoik asit türevlerini ve bu türevlerin yan etkilerini azaltmaya yönelik yapılan güncel çalışmaları incelemektir. Sonuç ve Tartışma: Akne vulgaris tedavisinde retinoidler ve antibiyotikler birbirini tamamlayan ajanlar olarak kullanılmaktadır. Retinoidler uzun vadeli çözüm sunarken antibiyotikler direnç gelişimi nedeniyle kısa süreli kullanılmaktadır. Sistemik olarak kullanılan tek retinoik asit türevi olan izotretinoin, şiddetli ve dirençli aknede hastalığın seyrine kalıcı olarak etki eden tek türevdir. Bu türevleri iyileştirmeye yönelik yapılan modifikasyonlar her ne kadar aktifliği ve seçiciliği değiştirse de bazı yan etkilerin devam ettiği görülmektedir. Bu nedenle bu yan etkileri minimuma indirecek formülasyonların optimize edilmesi akne tedavisindeki başarıyı arttıracaktır.

🔖

Cite This Article

Tarı, Ö., Tari, G., *, Ö. T. (2026). ACNE VULGARIS TREATMENT AND RETINOIC ACID DERIVATIVES. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 50 Sayı: 3, 860–878. https://doi.org/10.33483/jfpau.1712057

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (99)

  1. Burton, J., Cunliffe, W., Stafford, I., et al. (1971). The prevalence of acne vulgaris in adolescence. British Journal of Dermatology, 85(2), 119-126. [CrossRef]
  2. Akhavan, A., Bershad, S. (2003). Topical acne drugs: Review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology, 4, 473-492. [CrossRef]
  3. Feldman, S., Careccia, R.E., Barham, K.L. (2004). Hancox J. Diagnosis and treatment of acne. American Family Physician, 69(9), 2123-2130.
  4. Thiboutot, D., Gollnick, H., Bettoli, V., et al. (2009). New perspectives on the management of acne: An update from the Global Alliance to improve acne outcomes group. Journal of the American Academy of Dermatology, 60 (5), 1-50. [CrossRef]
  5. Choi, J.M., Lew, V.K., Kimball, A.B. (2006). A single‐blinded, randomized, controlled clinical trial evaluating the effect of face washing on acne vulgaris. Pediatric Dermatology, 23(5), 421-427. [CrossRef]
  6. Choi, Y.S., Suh, H.S., Yoon, M.Y., et al. (2010). A study of the efficacy of cleansers for acne vulgaris. Journal of Dermatological Treatment, 21(3), 201-205. [CrossRef]
  7. Tan, A.W., Tan, H.H. (2005). Acne vulgaris: A review of antibiotic therapy. Expert Opinion on Pharmacotherapy, 6(3), 409-418. [CrossRef]
  8. Leyden, J.J., Del Rosso, J.Q., Webster, G.F. (2009). Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: A status report. Dermatologic Clinics, 27(1), 1-15. [CrossRef]
  9. Yentzer, B.A., Irby, C.E., Fleischer, A.B., et al. (2008). Differences in acne treatment prescribing patterns of pediatricians and dermatologists: An analysis of nationally representative data. Pediatric Dermatology, 25(6), 635-639. [CrossRef]
  10. Zaenglein, A.L., Pathy, A.L., Schlosser, B.J., et al. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945-973. [CrossRef]
  11. Ward, A., Brogden, R.N., Heel, R.C., et al. (1984). Isotretinoin: A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs, 28, 6-37. [CrossRef]
  12. Leyden, J., Stein-Gold, L., Weiss, J. (2017). Why topical retinoids are mainstay of therapy for acne. Dermatology and Therapy, 7, 293-304. [CrossRef]
  13. Tan, J.K., Bhate, K. (2015). A global perspective on the epidemiology of acne. British Journal of Dermatology, 172(S1), 3-12. [CrossRef]
  14. Tuchayi, S.M., Makrantonaki, E., Ganceviciene, R., et al. (2015). Acne vulgaris. Nature Reviews: Disease Primers, 1(1), 15029. [CrossRef]
  15. Moore, A.Y., Hurley, K., Moore, S.A., et al. (2023). Effect of sarecycline on the acne symptom and ımpact scale and concerns in moderate-to-severe truncal acne in open-label pilot study. Antibiotics, 12(1), 94. [CrossRef]
  16. Pariser, D.M., Green, L.J., Lain, E.L., et al. (2019). Safety and tolerability of sarecycline for the treatment of acne vulgaris: Results from a phase III, multicenter, open-label study and a phase I phototoxicity study. The Journal of Clinical and Aesthetic Dermatology, 12(11), E53.
  17. Costa, C.S., Bagatin, E., Yang, Z., et al. (2021). Systemic pharmacological treatments for acne: An overview of systematic reviews. The Cochrane Database of Systematic Reviews, 11, CD014917. [CrossRef]
  18. Leung, A.K., Barankin, B., Lam, J.M., et al. (2021). Dermatology: How to manage acne vulgaris. Drugs in Context, 10. [CrossRef]
  19. Patel, M., Bowe, W.P., Heughebaert, C., et al. (2010). The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: A review. Journal of Drugs in Dermatology, 9(6), 655-664.
  20. Cooper, A.J. (1998). Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Medical Journal of Australia, 169(5), 259-261. [CrossRef]
  21. Lee, H., Hwang, D., Lee, M., et al. (2022). Micro-current stimulation suppresses inflammatory responses in peptidoglycan-treated raw 264.7 macrophages and Propionibacterium acnes-induced skin inflammation via TLR2/NF-κB signaling pathway. International Journal of Molecular Sciences, 23(5), 2508. [CrossRef]
  22. Nguyen, A.T., Kim, M., Kim, Y.E., et al. (2023). MSF Enhances Human Antimicrobial Peptide β-Defensin (HBD2 and HBD3) expression and attenuates inflammation via the NF-κ B and p38 signaling pathways. Molecules, 28(6), 2744. [CrossRef]
  23. Bershad, S.V. (2001). The modern age of acne therapy: A review of current treatment options. The Mount Sinai Journal of Medicine, New York, 68(4-5), 279-286.
  24. Mallon, E., Newton, J.N., Klassen, A., et al. (1999). The quality of life in acne: A comparison with general medical conditions using generic questionnaires. British Journal of Dermatology, 140(4), 672-676. [CrossRef]
  25. Smithard, A., Glazebrook, C., Williams, H.C. (2001). Acne prevalence, knowledge about acne and psychological morbidity in mid‐adolescence: A community‐based study. British Journal of Dermatology, 145(2), 274-279. [CrossRef]
  26. Layton, A., Alexis, A., Baldwin, H., et al. (2021). Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae by the Personalising Acne: Consensus of Experts panel. JAAD International, 5, 41-48. [CrossRef]
  27. Tan, J., Kang, S., Leyden, J. (2017). Prevalence and risk factors of acne scarring among patients consulting dermatologists in the USA. Journal of Drugs in Dermatology, 16(2), 97-102.
  28. Thiboutot, D.M., Dreno, B., Abanmi, A., et al. (2018). Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. Journal of the American Academy of Dermatology, 78(2), 1-23. [CrossRef]
  29. Bowe, W.P., Shalita, A.R. (2008). Effective over-the-counter acne treatments, 27(3), 170-176. [CrossRef]
  30. Baldwin, H.E., Lin, T. (2017). Management of severe acne vulgaris with topical therapy. Journal of Drugs in Dermatology, 16(11), 1134-1138.
  31. Chivot, M. (2005). Retinoid therapy for acne: A comparative review. American Journal of Clinical Dermatology, 6, 13-19. [CrossRef]
  32. Gollnick, H.P., Krautheim, A. (2003). Topical treatment in acne: Current status and future aspects. Dermatology, 206(1), 29-36. [CrossRef]
  33. Del Rosso, J.Q., Schmidt, N.F. (2010). A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris. Cutis, 85(1), 15-24.
  34. Mark, D.B., Hlatky, M.A. (2002). Medical economics and the assessment of value in cardiovascular medicine: Part I. Circulation, 106(4), 516-520. [CrossRef]
  35. Katsambas, A., Papakonstantinou, A. (2004). Acne: Systemic treatment. Clinics in Dermatology, 22(5), 412-418. [CrossRef]
  36. Kim, J.E., Park, A.Y., Lee, S.Y., et al. (2018). Comparison of the efficacy of azithromycin versus doxycycline in acne vulgaris: A meta-analysis of randomized controlled trials. Annals of Dermatology, 30(4), 417-426. [CrossRef]
  37. Del Rosso, J.Q. (2015). Oral doxycycline in the management of acne vulgaris: Current perspectives on clinical use and recent findings with a new double-scored small tablet formulation. The Journal of Clinical and Aesthetic Dermatology, 8(5), 19.
  38. Zhanel, G., Critchley, I., Lin, L.Y., et al. (2019). Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris. Antimicrobial Agents and Chemotherapy, 63(1), 10-1128. [CrossRef]
  39. Leyden, J.J., Del Rosso, J.Q. (2011). Oral antibiotic therapy for acne vulgaris: Pharmacokinetic and pharmacodynamic perspectives. The Journal of Clinical and Aesthetic Dermatology, 4(2), 40.
  40. Brown, S.K., Shalita, A.R. (1998). Acne vulgaris. Lancet, 351 (9119), 1871-1876. [CrossRef]
  41. Sunderkötter, C., Herrmann, M., Jappe, U. (2006). Antimicrobial therapy in dermatology. Journal der Deutschen Dermatologischen Gesellschaft, 4(1), 10-27. [CrossRef]
  42. Kawada, A., Wada, T., Oiso, N. (2012). Clinical effectiveness of once‐daily levofloxacin for inflammatory acne with high concentrations in the lesions. The Journal of Dermatology, 39(1), 94-96. [CrossRef]
  43. Cunliffe, W.J., Grosshans, E., Belaich, S., et al. (1998). A comparison of the efficacy and safety of lymecycline and minocycline in patients with moderately severe acne vulgaris. European Journal of Dermatology, 8(3), 161-166.
  44. Akamatsu, H., Nishijima, S., Akamatsu, M., et al. (1996). Clinical evaluation of roxithromycin in patients with acne. Journal of International Medical Research, 24(1), 109-114. [CrossRef]
  45. Tang, X.H., Gudas, L.J. (2011). Retinoids, retinoic acid receptors, and cancer. Annual Review of Pathology: Mechanisms of Disease, 6(1), 345-364. [CrossRef]
  46. Stepp, W. (1909). Versuche über Fütterung mit lipoidfreier Nahrung. Biochemischen Zeitschrift, 22, 452.
  47. Drummond, J.C. (1920). The nomenclature of the so-called accessory food factors (vitamins). Biochemical Journal, 14(5), 660. [CrossRef]
  48. Karrer, V.P., Morf, R., Schöpp, K. (1931). Zur Kenntnis des Vitamins‐A aus Fischtranen II. Helvetica Chimica Acta, 14(6), 1431-1436. [CrossRef]
  49. Isler, O., Huber, W., Ronco, A., et al. (1947). Synthese des vitamin A. Helvetica Chimica Acta, (6), 1911-1927. [CrossRef]
  50. Elder, J.T., Fisher, G.J., Zhang, Q.Y., et al. (1991). Retinoic acid receptor gene expression in human skin. Journal of Investigative Dermatology, 96(4), 425-433. [CrossRef]
  51. Gesto, M., Castro, L.F.C., Reis-Henriques, M.A., et al. (2012). Retinol metabolism in the mollusk Osilinus lineatus indicates an ancient origin for retinyl ester storage capacity. PLoS One, 7(4), e35138. [CrossRef]
  52. Martin, B., Meunier, C., Montels, D., et al. (1998). Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. British Journal of Dermatology, 139(52), 8-11. [CrossRef]
  53. Shroot, B., Michel, S., Galderma, F.C., et al. (1997). Pharmacology and chemistry of adapalene. Journal of the American Academy of Dermatology, 36(6), 96-103. [CrossRef]
  54. Nagpal, S., Chandraratna, R.A. (2000). Recent developments in receptor-selective retinoids. Current Pharmaceutical Design, 6(9), 919-931. [CrossRef]
  55. DiSepio, D., Sutter, M., Johnson, A.T., et al. (1999). Identification of the AP1-antagonism domain of retinoic acid receptors. Molecular Cell Biology Research Communications, 1(1), 7-13. [CrossRef]
  56. Jones, D.A. (2005). The potential immunomodulatory effects of topical retinoids. Dermatology Online Journal, 11(1), 3. [CrossRef]
  57. Abraham, D.J. (2003). Retinoids. Burger's Medicinal Chemistry and Drug Discovery, 5, 317-358.
  58. Lippman, S.M., Meyskens Jr, F.L. (1988). Vitamin A derivatives in the prevention and treatment of human cancer. Journal of the American College of Nutrition, 7(4), 269-284. [CrossRef]
  59. Stüttgen, G. (1986). Historical perspectives of tretinoin. Journal of the American Academy of Dermatology, 15(4), 735-740. [CrossRef]
  60. Spilovska, K., Zemek, F., Korabecny, J., et al. (2016). Adamantane a lead structure for drugs in clinical practice. Current Medicinal Chemistry, 23(29), 3245-3266. [CrossRef]
  61. Jain, S. (2004). Topical tretinoin or adapalene in acne vulgaris: An overview. Journal of Dermatological Treatment, 15(4), 200-207. [CrossRef]
  62. Zouboulis, C.C., Orfanos, C.E. (2000). Retinoids. Drug Therapy in Dermatology, 171-233.
  63. Goldsmith, L.A., Bolognia, J.L., Callen, J.P., et al. (2004). American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: Summary and recommendations. Journal of the American Academy of Dermatology, 50(6), 900-906. [CrossRef]
  64. Peck, G.L., Olsen, T.G., Yoder, F.W., et al. (1979). Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. New England Journal of Medicine, 300(7), 329-333. [CrossRef]
  65. Tsukada, M., Schröder, M., Orfanos, C.E., et al. (2000). 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. Journal of Investigative Dermatology, (2), 321-327. [CrossRef]
  66. Zouboulis, C. (2001). Exploration of retinoid activity and the role of inflammation in acne: Issues affecting future directions for acne therapy. Journal of the European Academy of Dermatology and Venereology, 15, 63-67. [CrossRef]
  67. Chandraratna, R.A.S. (1998). Rational design of receptor-selective retinoids. Journal of the American Academy of Dermatology, 39(4), 124-128. [CrossRef]
  68. Strauss, J.S., Krowchuk, D.P., Leyden, J.J., et al. (2007). Guidelines of care for acne vulgaris management. Journal of the American Academy of Dermatology, 56(4), 651-663. [CrossRef]
  69. Gold, L.F.S., Alexis, A.F., Harper, J.C., et al. (2018). Advances in acne and rosacea therapy. Dermatology, 37(3), 63-66. [CrossRef]
  70. Rusu, A., Tanase, C., Pascu, G.A., et al. (2020). Recent advances regarding the therapeutic potential of adapalene. Pharmaceuticals, 13(9), 217. [CrossRef]
  71. Sardana, K., Sehgal, V.N. (2003). Retinoids: fascinating up‐and‐coming scenario. The Journal of Dermatology, 30(5), 355-380. [CrossRef]
  72. Czernielewski, J., Michel, S., Bouclier, M., et al. (2001). Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne. Journal of the European Academy of Dermatology and Venereology, 15, 5-12. [CrossRef]
  73. Kryczyk-Poprawa, A., Kwiecien, A., Opoka, W. (2019). Photostability of topical agents applied to the skin: A review. Pharmaceutics, 12(1), 10. [CrossRef]
  74. Saple, D.G., Torsekar, R.G., Pawanarkar, V., et al. (2004). An open study to evaluate the efficacy and safety of tazarotene gel (0.1%) in acne vulgaris. Indian Journal of Dermatology Venereology and Leprology, 70, 92-95.
  75. Foster, R.H., Brogden, R.N., Benfield, P. (1998). Tazarotene. Drugs, 55(5), 705-711. [CrossRef]
  76. Webster, G.F., Guenther, L., Poulin, Y.P., et al. (2002). A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis, 69(2), 4-11.
  77. Chandraratna, R.A.S. (1996). Tazarotene-first of a new generation of receptor‐selective retinoids. British Journal of Dermatology, 135, 18-25. [CrossRef]
  78. Tanghetti, E.A., Zeichner, J.A., Gold, M., et al. (2023). Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin. Journal of Dermatological Treatment, 34(1), 2147391. [CrossRef]
  79. Gollnick, H., Schramm, M. (1998). Topical Drug Treatment in Acne. Dermatology, 196, 119-125. [CrossRef]
  80. Ferreira, R., Napoli, J., Enver, T., et al. (2020). Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine. Nature Communications, 11(1), 4265. [CrossRef]
  81. Yin, S., Luo, J., Qian, A., et al. (2013). Retinoids activate the irritant receptor TRPV1 and produce sensory hypersensitivity. The Journal of Clinical Investigation, 123(9), 3941-3951. [CrossRef]
  82. Tolleson, W.H., Cherng, S.H., Xia, Q. (2005). Photodecomposition and phototoxicity of natural retinoids. International Journal of Environmental Research and Public Health, 2(1), 147-155. [CrossRef]
  83. Kambayashi, H., Odake, Y., Takada, K., et al. (2005). N‐retinoyl‐d‐glucosamine, a new retinoic acid agonist, mediates topical retinoid efficacy with no irritation on photoaged skin. British Journal of Dermatology, 153(2), 30-36. [CrossRef]
  84. Kim, H., Kim, B., Kim, H., et al. (2008). Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative. Bioorganic & Medicinal Chemistry, 16(12), 6387-6393. [CrossRef]
  85. Kim, K.H., Lim, D.G., Lim, J.Y., et al. (2015). Chemical stability and in vitro and clinical efficacy of a novel hybrid retinoid derivative, bis-retinamido methylpentane. International Journal of Pharmaceutics, 495(1), 93-105. [CrossRef]
  86. Kim, H., Koh, J., Baek, J., et al. (2011). Retinyl retinoate, a novel hybrid vitamin derivative, improves photoaged skin: A double‐blind, randomized‐controlled trial. Skin Research and Technology, 17(3), 380-385. [CrossRef]
  87. Aubert, J., Piwnica, D., Bertino, B., et al. (2018). Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor‐γ agonist trifarotene. British Journal of Dermatology, 179(2), 442-456. [CrossRef]
  88. Blume‐Peytavi, U., Fowler, J., Kemeny, L., et al. (2020). Long‐term safety and efficacy of trifarotene 50 μg/g cream, a first‐in‐class RAR‐γ selective topical retinoid, in patients with moderate facial and truncal acne. Journal of the European Academy of Dermatology and Venereology, 34(1), 166-173. [CrossRef]
  89. Santhosh, P., Kidangazhiathmana, A. (2021). Trifarotene-the latest retinoid. Indian Journal of Dermatology, Venereology and Leprology, 87(5), 742-745. [CrossRef]
  90. Tan, J., Thiboutot, D., Popp, G., et al. (2019). Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. Journal of the American Academy of Dermatology, 80(6), 1691-1699. [CrossRef]
  91. Bai, D., Hu, F., Xu, H., et al. (2023). High stability and low irritation of retinol propionate and hydroxypinacolone retinoate supramolecular nanoparticles with effective anti-wrinkle efficacy. Pharmaceutics, 15(3), 731. [CrossRef]
  92. Temova Rakusa, Z., Skufca, P., Kristl, A., et al. (2021). Retinoid stability and degradation kinetics in commercial cosmetic products. Journal of Cosmetic Dermatology, 20(7), 2350-2358. [CrossRef]
  93. Podhorecka, M., Ibanez, B., Dmoszynska, A. (2017). Metformin-its potential anti-cancer and anti-aging effects. Advances in Hygiene & Experimental Medicine/Postepy Higieny i Medycyny Doswiadczalnej, 71(0),170-175. [CrossRef]
  94. Dessinioti, C., Dreno, B. (2020). Acne treatments: Future trajectories. Clinical and Experimental Dermatology, 45(8), 955-961. [CrossRef]
  95. EL‐Komy, M.H., Abdo, N.M.K., Shamma, R.N., et al. (2023). Topical metformin 30% gel in the treatment of acne vulgaris in women, a split face, placebo‐controlled study. Experimental Dermatology, 32(10), 1663-1673. [CrossRef]
  96. Natarelli, N., Gahoonia, N., Sivamani, R.K. (2023). Bacteriophages and the microbiome in dermatology: The role of the phageome and a potential therapeutic strategy. International Journal of Molecular Sciences, 24(3), 2695. [CrossRef]
  97. Castillo, D.E, Nanda, S., Keri, J.E. (2019). Propionibacterium (Cutibacterium) acnes bacteriophage therapy in acne: Current evidence and future perspectives. Dermatology and Therapy, 9, 19-31. [CrossRef]
  98. Liao, D., Zhang, J., Liu, R., et al. (2022). Whole-genome sequencing, annotation, and biological characterization of a novel Siphoviridae phage against multi-drug resistant Propionibacterium acne. Frontiers in Microbiology, 13, 1065386. [CrossRef]
  99. Kim, J.I., Hasnain, M.A., Moon, G.S. (2023). Expression of a recombinant endolysin from bacteriophage CAP 10-3 with lytic activity against Cutibacterium acnes. Scientific Reports, 13(1), 16430. [CrossRef]